We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: endocrine therapy
MedXY News
EnglishTag

endocrine therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating Lumpectomy Margin Thresholds in HR-Positive DCIS: Insights from the NRG Oncology/NSABP B-35 Trial
General SurgeryDuctal Carcinoma In Situendocrine therapy

Reevaluating Lumpectomy Margin Thresholds in HR-Positive DCIS: Insights from the NRG Oncology/NSABP B-35 Trial

By MedXY|Jul 5, 2026

This study evaluates the impact of lumpectomy margin widths on local recurrence in postmenopausal women with hormone receptor-positive DCIS undergoing lumpectomy, radiation, and endocrine therapy, suggesting minimal recurrence differences b

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer
newsCDK4/6 inhibitors
clinical trials

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer

By MedXY|Feb 23, 2026

A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer
newsendocrine therapyEndometrial Cancer

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer

By MedXY|Jan 13, 2026

Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str

Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer
newsendocrine therapyESR1 mutation

Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer

By MedXY|Jan 8, 2026

This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases o

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status
Neurologybreast cancercognitive impairment

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

By MedXY|Dec 17, 2025

A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.

Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent
newsendocrine therapy

Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent

By MedXY|Dec 15, 2025

Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alon

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis
OB/GYN & Women's Healthbreast cancerElinzanetant

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY|Oct 4, 2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

Extending Endocrine Treatment Duration for Early Breast Cancer
newsaromatase inhibitorsbreast cancer

Extending Endocrine Treatment Duration for Early Breast Cancer

By MedXY|Oct 4, 2025

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities